Redcare Pharmacy Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Olaf Heinrich
Chief executive officer
€1.1m
Total compensation
| CEO salary percentage | 44.26% |
| CEO tenure | 2.8yrs |
| CEO ownership | n/a |
| Management average tenure | 2.1yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Take Care Before Jumping Onto Redcare Pharmacy NV (ETR:RDC) Even Though It's 26% Cheaper
Redcare Pharmacy NV ( ETR:RDC ) shareholders that were waiting for something to happen have been dealt a blow with a...Take Care Before Jumping Onto Redcare Pharmacy NV (ETR:RDC) Even Though It's 26% Cheaper
The Redcare Pharmacy NV ( ETR:RDC ) share price has fared very poorly over the last month, falling by a substantial...Analyst Estimates: Here's What Brokers Think Of Redcare Pharmacy NV (ETR:RDC) After Its Second-Quarter Report
Shareholders might have noticed that Redcare Pharmacy NV ( ETR:RDC ) filed its second-quarter result this time last...Here's Why Redcare Pharmacy (ETR:RDC) Can Afford Some Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Redcare Pharmacy NV (ETR:RDC) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Investors in Redcare Pharmacy NV ( ETR:RDC ) had a good week, as its shares rose 2.9% to close at €127 following the...Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
eRx Surge And International Expansion Poised To Elevate Revenue And Profit Margins
Rapid expansion in new markets and tech-driven efficiencies suggest future revenue growth and improved profit margins.Here's Why Redcare Pharmacy (ETR:RDC) Can Afford Some Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Is There Now An Opportunity In Redcare Pharmacy NV (ETR:RDC)?
Redcare Pharmacy NV ( ETR:RDC ), is not the largest company out there, but it received a lot of attention from a...Are Investors Undervaluing Redcare Pharmacy NV (ETR:RDC) By 26%?
Key Insights Redcare Pharmacy's estimated fair value is €201 based on 2 Stage Free Cash Flow to Equity Current share...Investors Interested In Redcare Pharmacy NV's (ETR:RDC) Revenues
When you see that almost half of the companies in the Consumer Retailing industry in Germany have price-to-sales ratios...Redcare Pharmacy (ETR:RDC) Is Carrying A Fair Bit Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Why Investors Shouldn't Be Surprised By Redcare Pharmacy NV's (ETR:RDC) P/S
When close to half the companies in the Consumer Retailing industry in Germany have price-to-sales ratios (or "P/S...Is There An Opportunity With Redcare Pharmacy NV's (ETR:RDC) 48% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Redcare Pharmacy fair value estimate is €239 Redcare...Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Why Redcare Pharmacy NV (ETR:RDC) Could Be Worth Watching
Redcare Pharmacy NV ( ETR:RDC ), might not be a large cap stock, but it saw a significant share price rise of over 20...Why We're Not Concerned About Redcare Pharmacy NV's (ETR:RDC) Share Price
When close to half the companies in the Consumer Retailing industry in Germany have price-to-sales ratios (or "P/S...Broker Revenue Forecasts For Shop Apotheke Europe N.V. (ETR:SAE) Are Surging Higher
Shop Apotheke Europe N.V. ( ETR:SAE ) shareholders will have a reason to smile today, with the analysts making...Here's Why Shop Apotheke Europe (ETR:SAE) Can Afford Some Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -€37m |
| Dec 31 2025 | €1m | €500k | -€38m |
| Sep 30 2025 | n/a | n/a | -€35m |
| Jun 30 2025 | n/a | n/a | -€35m |
| Mar 31 2025 | n/a | n/a | -€48m |
| Dec 31 2024 | €930k | €500k | -€45m |
| Sep 30 2024 | n/a | n/a | -€25m |
| Jun 30 2024 | n/a | n/a | -€9m |
| Mar 31 2024 | n/a | n/a | -€10m |
| Dec 31 2023 | €569k | €208k | -€12m |
Compensation vs Market: Olaf's total compensation ($USD1.31M) is about average for companies of similar size in the German market ($USD1.11M).
Compensation vs Earnings: Olaf's compensation has increased whilst the company is unprofitable.
CEO
Olaf Heinrich (55 yo)
Mr. Olaf Heinrich is Chief Executive Officer and Member of the Managing Board at Redcare Pharmacy NV since August 01, 2023 and also served as its Interim Chief Financial Officer since September 26, 2025. M...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairperson of Supervisory Board | no data | €35.86k | 2.94% € 26.3m | |
| CEO & Member of Managing Board | 2.8yrs | €1.13m | no data | |
| Co-Founder & Member of Supervisory Board | no data | €28.94k | 0.26% € 2.3m | |
| Co-Founder & Advisor | 2.1yrs | no data | no data | |
| CFO & Member of Management Board | less than a year | €366.51k | no data | |
| COO & Member of the Managing Board | 10.3yrs | €735.02k | 0.74% € 6.6m | |
| Chief Information Officer & Member of Management Board | 2.1yrs | €592.47k | no data | |
| Associate Director of Investor Relations | no data | no data | no data | |
| Chief Sales Officer | no data | no data | no data | |
| Director of Human Resources | no data | no data | no data | |
| Chief E-Health Officer | no data | no data | no data | |
| Chief Product Officer - Retail | no data | no data | no data |
Experienced Management: RDC's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairperson of Supervisory Board | 1yr | €35.86k | 2.94% € 26.3m | |
| Co-Founder & Member of Supervisory Board | 1yr | €28.94k | 0.26% € 2.3m | |
| Independent Member of Supervisory Board | less than a year | no data | no data | |
| Independent Deputy Chairman of Supervisory Board | less than a year | no data | no data | |
| Independent Member of Supervisory Board | less than a year | no data | no data |
Experienced Board: RDC's board of directors are not considered experienced ( 0.1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/22 00:18 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Redcare Pharmacy NV is covered by 24 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gerhard Schwarz | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Sarah Roberts | Barclays |